Conclusions
Our study demonstrates reduction in postprandial glucose after exenatide injection in adolescents with type 1 diabetes. These effects were associated with delayed gastric emptying, and the results are consistent with published studies in adults.[13,14] However, as opposed to previous reports, glucagon suppression was not noted with exenatide, which could be because of the small sample size of our study.
Both exenatide doses were comparable in reducing postprandial glucose excursions, and hence the lower dose could be tested as an initial dose and titrated to response and tolerability in a larger cohort of subjects. Pharmacokinetic data are included in the online appendix (available at http://care.diabetesjournals.org/cgi/content/full/dc09-1959/DC1), and data are comparable to adults. Caution must be exercised if blood glucose is low to omit exenatide or use lowered insulin and/or exenatide dose.
In conclusion, adjunctive exenatide therapy has therapeutic potential in adolescents with type 1 diabetes. Further studies are ongoing using exenatide for a 4-month period.
Acknowledgments
R.A.H. received a grant from the National Institute of Health (grand R01DK077166-01). R.A.H. is a McNair scholar and was supported by The Robert and Janice McNair Foundation, McNair Scholars Program at Texas Children's Hospital. L.M.R. was supported by grant K23 DK075931. This study was also supported by General Clinical Research Center (GCRC) grant RR00188.
No potential conflicts of interest relevant to this article were reported.
We would like to thank Thanh Nguyen, MD, and staff of the GCRC and Texas Children's Hospital's investigational pharmacy for their assistance in conducting this study.
Diabetes Care. 2010;33(6):1294-1296. © 2010 American Diabetes Association, Inc.
Cite this: The Role of Adjunctive Exenatide Therapy in Pediatric Type 1 Diabetes - Medscape - Jun 01, 2010.
Comments